MYAM
Meiji Yasuda Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $728K | Sell |
5,793
-1,099
| -16% | -$138K | 0.04% | 286 |
|
|
2025
Q1 | $762K | Sell |
6,892
-368
| -5% | -$40.7K | 0.03% | 352 |
|
|
2024
Q4 | $991K | Hold |
7,260
| – | – | 0.04% | 312 |
|
|
2024
Q3 | $836K | Sell |
7,260
-24
| -0.3% | -$2.77K | 0.03% | 337 |
|
|
2024
Q2 | $1M | Buy |
7,284
+976
| +15% | +$134K | 0.04% | 306 |
|
|
2024
Q1 | $870K | Sell |
6,308
-2,732
| -30% | -$377K | 0.04% | 318 |
|
|
2023
Q4 | $1.19M | Buy |
9,040
+1,120
| +14% | +$148K | 0.05% | 292 |
|
|
2023
Q3 | $891K | Buy |
7,920
+4,980
| +169% | +$560K | 0.04% | 341 |
|
|
2023
Q2 | $277K | Buy |
2,940
+580
| +25% | +$54.6K | 0.01% | 522 |
|
|
2023
Q1 | $239K | Sell |
2,360
-3,930
| -62% | -$398K | 0.01% | 540 |
|
|
2022
Q4 | $751 | Hold |
6,290
| – | – | 0.04% | 359 |
|
|
2022
Q3 | $668K | Sell |
6,290
-140
| -2% | -$14.9K | 0.04% | 371 |
|
|
2022
Q2 | $627K | Buy |
6,430
+120
| +2% | +$11.7K | 0.04% | 401 |
|
|
2022
Q1 | $592K | Sell |
6,310
-120
| -2% | -$11.3K | 0.03% | 422 |
|
|
2021
Q4 | $548K | Buy |
+6,430
| New | +$548K | 0.03% | 372 |
|
|
2021
Q2 | – | Sell |
-4,900
| Closed | -$477K | – | 520 |
|
|
2021
Q1 | $477K | Buy |
4,900
+410
| +9% | +$39.9K | 0.04% | 354 |
|
|
2020
Q4 | $430K | Buy |
+4,490
| New | +$430K | 0.04% | 286 |
|